Editor’s foreword to the inaugural issue of Tumor Discovery

© 2022 by the Authors. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution 4.0 International License ( https://creativecommons.org/licenses/by/4.0/ )

Download PDF

Cite

XML

References

[1]

Bray F, Laversanne M, Weiderpass E, et al., 2021, The ever-increasing importance of cancer as a leading cause of premature death worldwide. Cancer, 127(16): 3029–3030. https://doi.org/10.1002/cncr.33587

[2]

Sung H, Ferlay J, Siegel RL, et al., 2021, Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin, 71: 209–249. https://doi.org/10.3322/caac.21660

[3]

Lee YT, Tan YJ, Oon CE, 2018, Molecular targeted therapy: Treating cancer with specificity. Eur J Pharmacol, 834: 188–196. https://doi.org/10.1016/j.ejphar.2018.07.034

[4]

Ruiz-Cordero R, Devine WP, 2020, Targeted therapy and checkpoint immunotherapy in lung cancer. Surg Pathol Clin, 13(1): 17–33. https://doi.org/10.1016/j.path.2019.11.002

[5]

Zhong L, Li Y, Xiong L, et al., 2021, Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives. Signal Transduct Target Ther, 6(1): 201. https://doi.org/10.1038/s41392-021-00572-w

[6]

Dhar R, Seethy A, Singh S, et al., 2021, Cancer immunotherapy: Recent advances and challenges. J Cancer Res Ther, 17(4): 834–844. https://doi.org/10.4103/jcrt.jcrt_1241_20

[7]

Taefehshokr S, Parhizkar A, Hayati S, et al., 2022, Cancer immunotherapy: Challenges and limitations. Pathol Res Pract, 229: 153723. https://doi.org/10.1016/j.prp.2021.153723

[8]

Kraehenbuehl L, Weng CH, Eghbali S, et al., 2022, Enhancing immunotherapy in cancer by targeting emerging immunomodulatory pathways. Nat Rev Clin Oncol, 19(1): 37–50. https://doi.org/10.1038/s41571-021-00552-7

[9]

Zhang Y, Zhang Z, 2020, The history and advances in cancer immunotherapy: Understanding the characteristics of tumor-infiltrating immune cells and their therapeutic implications. Cell Mol Immunol, 17(8): 807–821. https://doi.org/10.1038/s41423-020-0488-6

[10]

Torre LA, Bray F, Siegel RL, et al., 2015, Global cancer statistics, 2012. CA Cancer J Clin, 65(2): 87–108. https://doi.org/10.3322/caac.21262

[11]

Majd MH, 2022, Dual-targeting and specific delivery of tamoxifen to cancer cells by modified magnetic nanoparticles using hyaluronic acid and folic acid. Tumor Discov, 1(1): 41. https://doi.org/10.36922/td.v1i1.41

[12]

Wefel JS, Kesler SR, Noll KR, et al., 2015, Clinical characteristics, pathophysiology, and management of noncentral nervous system cancer-related cognitive impairment in adults. CA Cancer J Clin, 65: 123–138. https://doi.org/10.3322/caac.21258

[13]

Jiang J, Du Z, Wang Y, et al., 2022, Advances in the study of the pathogenesis of cancer-related cognitive impairment. Tumor Discov, 1(1): 46. https://doi.org/10.36922/td.v1i1.46

[14]

Shi S, Zhang ZG, Ma GY, et al., 2022, The clinicopathological and prognostic significance of PD-1 expression in cancers: A bioinformatics analysis. Tumor Discov, 1(1): 59. https://doi.org/10.36922/td.v1i1.59

[15]

Fu X, Yin M, 2022, Monocytes in tumor: The perspectives of single-cell analysis. Tumor Discov, 1(1): 4. https://doi.org/10.36922/td.v1i1.4

[16]

Jiang Z, Li H, Li F, 2022, Combined anti-PD1 immunotherapy for patient with advanced pancreatic cancer: A case report. Tumor Discov, 1(1): 52. https://doi.org/10.36922/td.v1i1.52

Conflict of interest

The author declares no potential conflicts of interest.

Previous article in this issue

Next article in this issue

Tumor Discovery, Electronic ISSN: 2810-9775 Published by AccScience Publishing